Table 1.
In vitro and in vivo selection of de novo primarily elvitegravir-associated resistance substitutions in HIV IN in tissue culture and in INSTI-naïve individuals
| Substitutions | RAL | EVG | DTG | |||
|---|---|---|---|---|---|---|
| Selection | In vitro | In vivo | In vitro | In vivo | In vitro | In vivo |
| T66 | ||||||
| T66A | X | X | X | X | ||
| T66I | X | X | ||||
| T66I/V72A/A128T | X | |||||
| T66I/E92Q | X | |||||
| T66I/E92Q/T124A | X | |||||
| T66I/Q95K/E138K/Q146P/S147G | X | |||||
| T66I/T97A/G163R | X | |||||
| T66I/T124A | X | |||||
| T66I/T124A/Q146L | X | |||||
| T66I/I203M | X | |||||
| T66I/F121Y/S153Y/D232N | X | |||||
| T66I/D232N | X | |||||
| T66I/R263K | X | |||||
| T66K | X | X | X | |||
| T66K/L74M | X | |||||
| T124A/T66K | X | X | ||||
| E92 | ||||||
| E92G | X | |||||
| E92Q | X | X | X | X | X | |
| L74M/E92Q | X | |||||
| H51Y/E92Q/S147G | X | |||||
| H51Y/E92Q/S147G/E157Q | X | |||||
| E92Q/M154I | X | |||||
| E92V | X | |||||
| E92V/T124A | X | |||||